Clinical Characteristics and Outcomes in Patients with Chronic HBV Infection and Hospitalized for COVID-19 Pneumonia: A Retrospective Cohort Study DOI Creative Commons
Lucio Boglione,

Maria Grazia Crobu,

Mario Pirisi

et al.

Viruses, Journal Year: 2024, Volume and Issue: 17(1), P. 40 - 40

Published: Dec. 30, 2024

The effects of a concomitant infection hepatitis B virus (HBV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are still debated, with recognized major risk HBV reactivation during immune-suppressive treatments. aim this study was to determine the prevalence predictive factors in cohort hospitalized patients disease 2019 (COVID-19) current or past infection. In monocentric retrospective observational study, we enrolled all consecutive hospital admitted COVID-19 pneumonia positive serology (N = 84) our Infectious Diseases Unit from April 2021 December 2023. We identified 18 (21%) HBsAg-positive/anti-HBc-positive, 41 (49%) HBsAg-negative/anti-HBc-positive/anti-HBs-positive, 25 (30%) HBsAg-negative/anti-HBc-positive/anti-HBs-negative subjects. overall rate flare 10.7%, without any HBsAg seroreversion, reactivation, and/or need for new antiviral therapy introduction. Systemic corticosteroid treatment baseline anti-HBsAg status were associated reactivation. conclusion, flares reasonably low, higher doses corticosteroids being factor anti-HBs-positive serological as protective element.

Language: Английский

Clinical Characteristics and Outcomes in Patients with Chronic HBV Infection and Hospitalized for COVID-19 Pneumonia: A Retrospective Cohort Study DOI Creative Commons
Lucio Boglione,

Maria Grazia Crobu,

Mario Pirisi

et al.

Viruses, Journal Year: 2024, Volume and Issue: 17(1), P. 40 - 40

Published: Dec. 30, 2024

The effects of a concomitant infection hepatitis B virus (HBV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are still debated, with recognized major risk HBV reactivation during immune-suppressive treatments. aim this study was to determine the prevalence predictive factors in cohort hospitalized patients disease 2019 (COVID-19) current or past infection. In monocentric retrospective observational study, we enrolled all consecutive hospital admitted COVID-19 pneumonia positive serology (N = 84) our Infectious Diseases Unit from April 2021 December 2023. We identified 18 (21%) HBsAg-positive/anti-HBc-positive, 41 (49%) HBsAg-negative/anti-HBc-positive/anti-HBs-positive, 25 (30%) HBsAg-negative/anti-HBc-positive/anti-HBs-negative subjects. overall rate flare 10.7%, without any HBsAg seroreversion, reactivation, and/or need for new antiviral therapy introduction. Systemic corticosteroid treatment baseline anti-HBsAg status were associated reactivation. conclusion, flares reasonably low, higher doses corticosteroids being factor anti-HBs-positive serological as protective element.

Language: Английский

Citations

0